8.1 USD
+0.17 (+2.14%)
8.08 USD
-0.02 (-0.25%)
We assign a fundamental rating of 2 out of 10 to VNDA. VNDA was compared to 525 industry peers in the Biotechnology industry. There are concerns on the financial health of VNDA while its profitability can be described as average. VNDA has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year VNDA has reported negative net income.
- VNDA had a negative operating cash flow in the past year.
- Of the past 5 years VNDA 4 years were profitable.
- Of the past 5 years VNDA 4 years had a positive operating cash flow.
1.2 Ratios
- The Return On Assets of VNDA (-14.01%) is better than 80.76% of its industry peers.
- VNDA has a better Return On Equity (-18.07%) than 84.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.01% | ||
| ROE | -18.07% | ||
| ROIC | N/A |
ROA(3y)-0.5%
ROA(5y)1.69%
ROE(3y)-0.62%
ROE(5y)1.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of VNDA (94.44%) is better than 95.05% of its industry peers.
- In the last couple of years the Gross Margin of VNDA has remained more or less at the same level.
- The Profit Margin and Operating Margin are not available for VNDA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.44% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.39%
GM growth 5Y1.12%
2. Health
2.1 Basic Checks
- VNDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- VNDA has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, VNDA has more shares outstanding
- Compared to 1 year ago, VNDA has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of 1.72, we must say that VNDA is in the distress zone and has some risk of bankruptcy.
- With a decent Altman-Z score value of 1.72, VNDA is doing good in the industry, outperforming 65.52% of the companies in the same industry.
- A Debt/Equity ratio of 0.01 indicates that VNDA is not too dependend on debt financing.
- VNDA has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: VNDA outperforms 46.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.72 |
ROIC/WACCN/A
WACC8.87%
2.3 Liquidity
- VNDA has a Current Ratio of 3.12. This indicates that VNDA is financially healthy and has no problem in meeting its short term obligations.
- VNDA has a worse Current ratio (3.12) than 62.86% of its industry peers.
- A Quick Ratio of 3.10 indicates that VNDA has no problem at all paying its short term obligations.
- VNDA has a worse Quick ratio (3.10) than 60.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
- VNDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -407.14%.
- Looking at the last year, VNDA shows a quite strong growth in Revenue. The Revenue has grown by 11.12% in the last year.
- The Revenue has been decreasing by -2.64% on average over the past years.
EPS 1Y (TTM)-407.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-322.22%
Revenue 1Y (TTM)11.12%
Revenue growth 3Y-9.56%
Revenue growth 5Y-2.64%
Sales Q2Q%18.06%
3.2 Future
- VNDA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -46.02% yearly.
- Based on estimates for the next years, VNDA will show a small growth in Revenue. The Revenue will grow by 1.13% on average per year.
EPS Next Y-635.52%
EPS Next 2Y-121.38%
EPS Next 3Y-46.02%
EPS Next 5YN/A
Revenue Next Year9.44%
Revenue Next 2Y16.63%
Revenue Next 3Y20.31%
Revenue Next 5Y1.13%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for VNDA. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VNDA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- VNDA's earnings are expected to decrease with -46.02% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-121.38%
EPS Next 3Y-46.02%
5. Dividend
5.1 Amount
- No dividends for VNDA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
VANDA PHARMACEUTICALS INC / VNDA FAQ
What is the ChartMill fundamental rating of VANDA PHARMACEUTICALS INC (VNDA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to VNDA.
What is the valuation status of VANDA PHARMACEUTICALS INC (VNDA) stock?
ChartMill assigns a valuation rating of 0 / 10 to VANDA PHARMACEUTICALS INC (VNDA). This can be considered as Overvalued.
What is the profitability of VNDA stock?
VANDA PHARMACEUTICALS INC (VNDA) has a profitability rating of 4 / 10.
Can you provide the financial health for VNDA stock?
The financial health rating of VANDA PHARMACEUTICALS INC (VNDA) is 3 / 10.
What is the expected EPS growth for VANDA PHARMACEUTICALS INC (VNDA) stock?
The Earnings per Share (EPS) of VANDA PHARMACEUTICALS INC (VNDA) is expected to decline by -635.52% in the next year.